The Economics of a Longevity Clinic: An Auditable Operating Model

Originally published June 11, 2026; evidence and rules reviewed through September 17, 2026. Illustrative economics are assumptions, not industry benchmarks. This is not medical, legal or investment advice.

Executive view

There is no defensible universal margin for a “longevity clinic.” The label can describe a physician practice, a membership programme, a diagnostic centre, a telehealth service, a procedure-led operator, or a hybrid that sells tests and products. Each has different capacity, variable cost, regulatory exposure and revenue recognition.

The useful question is not where margins “actually” come from. It is whether an operator can show, line by line, how collected revenue becomes contribution after clinician time, tests, imaging, supplies, support, payment costs and expected refunds—and whether the services themselves meet appropriate evidence, licensing, privacy and advertising standards.

The regulatory examples below are U.S.-specific. CMS/CLIA, HHS/HIPAA and FTC guidance do not govern clinics globally, and they do not replace U.S. state rules or the laws of another country. A clinic operating elsewhere needs a jurisdiction-specific analysis.

Define the service model before the margin

Start with five facts: who employs or contracts the clinicians; what is included in the membership; which services are performed internally; which are purchased from laboratories or imaging partners; and which products create a separate financial interest. A clinic that bundles annual interpretation and care coordination is economically different from one that relies on frequent procedures or product resale.

Revenue should be separated into membership or subscription fees, clinical encounters, laboratory and diagnostic services, imaging, procedures, pharmacy or supplement sales, employer contracts, and research or data arrangements. Gross billings are not cash collected. Refunds, discounts, chargebacks, insurer denials and pass-through payments need their own lines.

Capacity is usually the binding variable

For a clinician-led model, appointment capacity can be expressed as:

available clinical minutes × realistic utilization ÷ minutes per member episode.

Realistic utilization excludes documentation, case review, coordination, training, leave and unavoidable gaps. If an annual membership promises multiple physician reviews, asynchronous messages and complex interpretation, the included work must be converted into minutes. Selling more memberships than the team can safely support may improve cash temporarily while degrading access and retention.

A transparent revenue stack

Clinical laboratory activity has a real compliance perimeter. CMS states that CLIA applies to all U.S. and CLIA-certified international laboratories or sites that test human specimens—including blood, tissue and body fluid—to assess health or to diagnose, prevent or treat disease; certificate and personnel requirements vary with test complexity CMS CLIA regulations and compliance and CMS certificate guidance. A clinic cannot assume that bringing testing in-house converts an external bill into uncomplicated margin.

Direct service cost and overhead

Variable cost should include clinician and support time attributable to the service, external laboratory and imaging invoices, collection materials, procedure supplies, payment fees, shipping, and expected refunds or rework. Semi-fixed and fixed cost should include non-billable clinical leadership, facilities, equipment leases and maintenance, malpractice coverage, licensure, software, cybersecurity, compliance, quality systems and administration.

Privacy cost depends on the actual U.S. relationships and data flows. HHS distinguishes covered entities and business associates; HIPAA obligations and business-associate contracting requirements apply when the actors and activities actually meet those definitions HHS covered entities and business associates and HHS business-associate contracts. A clinic, vendor or data relationship should not be described as “HIPAA compliant” merely because it handles health-related information. “Data platform” revenue therefore cannot be evaluated without consent, permitted-use and governance assumptions.

An illustrative unit-economics model

The following is a sensitivity example, not observed operator data.

Assume 1,000 active members. Monthly membership revenue is an assumed $250 per member, or $250,000. Assume $80 per member-month of included variable clinical and diagnostic cost, producing $170,000 before acquisition, fixed overhead and taxes. If monthly member churn is 2%, the simple expected membership life is about 50 months; at 5%, it is about 20 months. That difference radically changes how much acquisition spending can be recovered.

These numbers demonstrate sensitivity, not attractiveness. A small change in utilization, service intensity, churn or clinician staffing can reverse the result. The model should be rebuilt from an operator’s actual contracts, payroll, utilization and cash collections.

Acquisition, retention and referral dependence

Customer acquisition cost must include paid media, sales labour, referral fees where lawful, events, discounts and the cost of unconverted leads. Lifetime-value calculations should use contribution after variable service cost, not revenue. They should also test whether early cohorts behave differently from mature cohorts.

Referral dependence matters in both directions. An operator may rely on third-party imaging and specialists, limiting schedule control and economics. Conversely, owning every service can increase capital intensity, conflicts and compliance obligations. The best structure is not necessarily the one with the most captured revenue.

Evidence and commercial claims

For U.S. advertising, FTC health-product guidance explains that the amount and type of substantiation depend on the specific claim, product and surrounding context; health-related efficacy and safety claims generally require competent and reliable scientific evidence appropriate to that claim FTC Health Products Compliance Guidance. Marketing a large testing menu or proprietary score does not establish clinical utility. A responsible economic model includes the cost of evidence review, informed consent, adverse-event handling, referral and escalation—not only the revenue from the service.

What this establishes

A clinic’s economics can be audited through units: active members, collected revenue, promised service minutes, utilization, variable delivery cost, acquisition, churn and fixed infrastructure. The framework exposes which assumptions drive sustainability and which revenues carry compliance or conflict risk.

What this does not establish

The model does not provide an industry-average margin, value a particular clinic, endorse a service, or show that a profitable service improves health outcomes. It does not replace jurisdiction-specific accounting, reimbursement, clinical or legal review.

Sources and evidence

• CMS: CLIA Regulations & Compliance
• CMS: Apply for a CLIA Certificate
• HHS: Covered Entities and Business Associates
• HHS: Business Associate Contracts
• FTC: Health Products Compliance Guidance

What would change this assessment

This assessment should be revisited if an operator publishes audited segment economics; reimbursement or laboratory rules materially change; an enforcement action clarifies advertising or data practices; or validated outcomes support a stronger connection between service use and patient benefit.